Citi upgraded Bio-Techne (TECH) to Buy from Neutral with a price target of $70, up from $55. The firm views the company’s growth and margin outlook as conservative and believes the stock is undervalued at current levels. Easing tariffs, growth in China and margin expansion could drive upside to Bio-Techne’s guidance, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Strategic Divestiture and Focus on Core Strengths Justify Buy Rating for Bio-Techne
- Bio-Techne’s Strong Q4 Performance and Strategic Moves Justify Buy Rating
- Bio-Techne Reports Solid Q4 2025 Results Amid Strategic Shift
- Bio-Techne’s Earnings Call: Growth Amid Challenges
- Bio-Techne reports Q4 adjusted EPS 53c, consensus 50c